Gilead Sciences, Inc. (GILD) Wednesday announced positive results from two-year interim analysis of the ongoing ASSURE study evaluating the company's investigational drug seladelpar for the treatment of primary biliary cholangitis (PBC), a rare, chronic inflammatory liver disease.
The two-year interim analysis included patients who participated in any prior clinical studies of seladelpar (legacy studies) and participants from the pivotal Phase 3 RESPONSE study. The positive results from the two-year interim analysis were highly consistent with one-year interim analysis.
Results from the study showed rapid and sustained improvements in markers of cholestasis, including high rates of normalization of liver biomarkers and a clinically meaningful reduction in pruritus in patients treated with seladelpar.
These data were shared in a presentation during the European Association for the Study of the Liver (EASL) Congress 2024 in Milan, Italy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.